Skip to main content

Table 1 Early-stage technology companies

From: Valuation method by regression analysis on real royalty-related data by using multiple input descriptors in royalty negotiations in Life Science area-focused on anticancer therapies

Company Technology Disease area R&D status Market capitalization
StemCells Cell therapy Diabetes, Parkinson’s Preclinicals $55 million
Transition Therapeutics Biopharma Diabetes Phase I $78 million
Alteon Biopharma Diabetes, Aging Phase II, Preclinicals $69 million
Aradigm Medical devices Diabetes Phase II, III $134 million
Aastrom Biosciences Cell theraphy Oncology, Dermatology Phase I $83 million
Emisphere Technologies Medical devices Diabetes, Blood system Phase I, II, III $109 million
NeoPharm Biopharma Oncology Phase,I, II $476 million
ConjuChem Biopharma Deabetes, AIDS, CHF Phase II $589 million
Spectrum Pharma Biopharma Oncology, Neurology Preclinicals $79 million
Ergo Sciences Biopharma Diabetes Technology sold $15 million